NCT07312903

DPTX3186 in Wnt Pathway Activated Solid Tumors

An Open Label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects With Known Wnt Pathway Activated Solid Tumors Where No Other Treatments Exist

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Dewpoint Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	DPTX3186	Once daily (single dose of study drug in the morning in fasted conditions) for 4 consecutive days (4 days on) and 3 days off in a cycle of 28 days

Timeline

• Start date: 2026-01-01
• Primary completion: 2028-05-31
• Completion: 2028-06-30
• First posted: 2025-12-31
• Last updated: 2026-01-12

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study